Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity

Vaccine

Volumn 18, Issue 27, 2000, Pages 3141-3151

  Marciani, D J ^a   Press, J B ^a   Reynolds, R C ^b   Pathak, A K ^b   Pathak, V ^b   Gundy, L E ^b   Farmer, J T ^b   Koratich, M S ^b   May, R D ^b  

^a Galenica Pharmaceuticals Inc   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; Quillaja saponaria; Saponin analogs

Indexed keywords

ADJUVANT; GPI 0100; SAPONIN DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SYNTHESIS; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; LIVER FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

QUILLAJA SAPONARIA;

EID: 0034662482     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00118-3     Document Type: Article

References (41)

1. Stenger S., Modin R.L. Cytotoxic T cell responses to intracellular pathogens. Curr. Opin. Immunol. 10:1998;471-477.
2. Vile R.G., Chong H., Dorudi S. The immunesurveillance of cancer: specific and nonspecific mechanisms. Dagleish A.G., Browning M. Tumor immunology. 1996;7-38 Cambridge University Press, Cambridge.
3. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15:1997;248-256.
4. Kwak L.W., Longo D.L. Modern vaccine adjuvants. Chabner B.A., Longo D.L. Cancer Chemotherapy and Biotherapy. 1996;749-763 Lippincott-Raven, Philadelphia, PA.
5. Macy D.W. Vaccine adjuvants. Semin. Vet. Surg. 12:1997;206-211.
6. Elson C.O., Dertzbaugh M.T. Mucosal adjuvant. Handbook of mucosal immunology. 1994;391-402 Academic Press, New York.
7. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:1991;431-437.
8. van Setten D.C., van de Werken G. Molecular structures of saponins from Quillaja saponaria Molina. Adv. Exp. Med. Biol. 404:1996;185-193.
9. Nord L.I., Kenne L. Separation and structural analysis of saponins in a bark extract from Quillaja saponaria Molina. Carbohydr. Res. 320:1999;70-81.
10. Kensil C.R., Wu J.Y., Anderson C.A., Wheeler D.A., Amsden J. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92:1998;41-47.
11. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope proteins in ISCOMS. Nature. 344:1990;873-875.
12. Wu J.-Y., Gardner B.H., Murphy C.I., et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 148:1992;1519-1525.
13. Soltysik S., Wu J.-Y., Recchia J., et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine. 13:1995;1403-1410.
14. Press JB, Reynolds RC, May RD, Marciani DJ. Structure/function relationships of immunostimulating saponins. Stud Nat Prod Chem, in press.
15. Bomford R., Stapleton M., Winsor S., et al. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine. 10:1992;572-577.
16. Higuchi R., Tokimitsu Y., Komori T. An acylated triterpenoid saponin from Quillaja saponaria. Phytochemistry. 27:1988;1165-1168.
17. Kensil C, Soltysik S, Marciani DJ. 1996; US Patent 5,583,112.
18. Jiang W., Swiggard W.J., Heufler C., et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 375:1995;151-155.
19. Stahl P.D. The mannose receptor and other macrophage lectins. Curr. Opin. Immunol. 4:1992;49-52.
20. Kensil C., Soltysik S., Patel U., Marciani D.J. Structure-function relationship in adjuvants from Quillaja saponaria Molina. Brown F., Chanock R.M., Ginsberg H.S., Lerner R.A. Vaccines 92. 1992;35-40 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
21. Pillion D.J., Recchia J., Wang P., Marciani D.J., Kensil C. DS-1, a modified Quillaja saponin, enhances ocular and nasal absorption of insulin. J. Pharm. Sci. 84:1995;1276-1279.
22. Cleland J.L., Kensil C.R., Lim A., et al. Isomerization and formulation stability of the vaccine adjuvant QS-21. J. Pharm. Sci. 85:1996;22-28.
23. Kensil C.R., Wu J.Y., Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm. Biotechnol. 6:1995;525-541.
24. Bauminger S., Wilchek M. The use of carbodiimides in the preparation of immunizing conjugates. Methods Enzymol. 70:1980;151-159.
25. Parikh I., March S., Cuatrecasas P. Topics in the methodology of substitution reactions with agarose. Methods Enzymol. 34:1974;77-102.
26. Newman M.J., Wu J.-Y., Gardner B.H., et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148:1992;2357-2362.
27. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:1988;777-785.
28. Kensil C, Beltz GPCT. 1999; International Patent Publication WO 99/10008.
29. Hostettmann K., Marston A. Saponins. 1995;Cambridge University Press, Cambridge.
30. Johnston D.E. Special considerations in interpreting liver functions tests. Am. Fam. Phys. 59:1999;2223-2230.
31. Stevens T.L., Bossie A., Sanders V.M., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 334:1988;255-258.
32. Long D., Madara T.J., Ponce de Leon M., Cohen G.H., Montgomery P.C., Eisenberg R.J. Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect. Immun. 43:1984;761-764.
33. Bowyer P., Clarke B.R., Lunness P., Daniels M.J., Osbourn A.E. Host range of a plant pathogenic fungus determined by a saponin detoxifying enzyme. Science. 267:1995;371-374.
34. Rhodes J., Chen H., Hall S.R., et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature. 377:1995;71-75.
35. Rhodes J. Covalent chemical events in immune induction: fundamental and therapeutic aspects. Immunol. Today. 17:1996;436-441.
36. Alexandroff A.B., Robins R.A., Murray A., James K. Tumour immunology: false hopes - new horizons? Immunol. Today. 19:1998;247-250.
37. Pedersen N.C., Johnson L., Birch D., Theilen G.H. Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge exposure situations where whole inactivated virus vaccines were protective. Vet. Immunol. Immunopathol. 11:1986;123-148.
38. Beltz GA, Marciani DJ, Hung CH, Kensil CA. 1994; US Patent 5,352,449.
39. Manson L.A. Anti-tumor immune responses of the tumor-bearing host: the case for antibody-mediated immunologic enhancement. Clin. Immunol. Immunopathol. 72:1994;1-8.
40. Jett M., Alving C.R. Selective cytotoxicity of tumor cells induced by liposomes containing plant phosphatidylinositol. Biochem. Biophys. Res. Commun. 114:1983;863-871.
41. Jett M., Chudzik J., Alving C.R., Stanacev N.Z. Metabolic fate of liposomal phosphatidylinositol in murine tumor cells: implications for the mechanism of tumor cell cytotoxicity. Cancer Res. 45:1985;4810-4815.